BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Portuguese AJ, Lipe B. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv 2018;2:3443-6. [PMID: 30518536 DOI: 10.1182/bloodadvances.2018027532] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Blasco M, Martínez-Roca A, Rodríguez-Lobato LG, Garcia-Herrera A, Rosiñol L, Castro P, Fernández S, Quintana LF, Cibeira MT, Bladé J, Fernández de Larrea C, Tovar N, Jimenez R, Poch E, Guillen E, Campistol JM, Carreras E, Diaz-Ricart M, Palomo M. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol 2021;193:181-7. [PMID: 32469083 DOI: 10.1111/bjh.16796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Jeyaraman P, Borah P, Singh A, Chhabra GD, Khullar D, Dayal N, Naithani R. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient. Blood Cells Mol Dis 2020;81:102400. [PMID: 31887694 DOI: 10.1016/j.bcmd.2019.102400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Freyer CW, Bange EM, Skuli S, Hsu M, Lin J, Cuker A, Cohen AD, Garfall A. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00248-2. [PMID: 34366267 DOI: 10.1016/j.clml.2021.06.019] [Reference Citation Analysis]
4 Caroti L, Cestone G, Di Maria L, Allinovi M, Li Marzi V, Serni S, Cirami CL. Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report. Clin Nephrol Case Stud 2021;9:59-66. [PMID: 34084691 DOI: 10.5414/CNCS110434] [Reference Citation Analysis]
5 Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol 2021;193:750-60. [PMID: 33650100 DOI: 10.1111/bjh.17377] [Reference Citation Analysis]
6 Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol 2020;99:1265-71. [DOI: 10.1007/s00277-020-04062-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kozlowski P, Kameran Behnam K, Uggla B, Åström M. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Eur J Haematol 2020;104:588-93. [PMID: 32115785 DOI: 10.1111/ejh.13401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, Nada R, Sethi J, Ahluwalia J, Malhotra P. Carfilzomib-induced thrombotic microangiopathy: A case based review. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30118-7. [PMID: 32735793 DOI: 10.1016/j.hemonc.2020.07.001] [Reference Citation Analysis]
9 Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clinical Lymphoma Myeloma and Leukemia 2020;20:e155-7. [DOI: 10.1016/j.clml.2020.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Rassner M, Baur R, Wäsch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol 2021;22:32. [PMID: 33461512 DOI: 10.1186/s12882-020-02226-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yee AJ. The role of carfilzomib in relapsed/refractory multiple myeloma. Ther Adv Hematol 2021;12:20406207211019612. [PMID: 34163580 DOI: 10.1177/20406207211019612] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 2021;14:e239091. [PMID: 33637496 DOI: 10.1136/bcr-2020-239091] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Fotiou D, Roussou M, Gakiopoulou C, Psimenou E, Gavriatopoulou M, Migkou M, Kanellias N, Dialoupi I, Eleutherakis-Papaiakovou E, Giannouli S, Delavinia C, Efstathiou K, Kontogiannis S, Terpos E, Dimopoulos MA, Kastritis E. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer J 2020;10:109. [PMID: 33149167 DOI: 10.1038/s41408-020-00381-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE, Hay AE. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. Am J Hematol 2021;96:552-60. [PMID: 33650179 DOI: 10.1002/ajh.26147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Reference Citation Analysis]
16 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020;95:672-90. [PMID: 32086970 DOI: 10.1002/ajh.25764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
18 Chatzikonstantinou T, Gavriilaki M, Anagnostopoulos A, Gavriilaki E. An Update in Drug-Induced Thrombotic Microangiopathy. Front Med (Lausanne). 2020;7:212. [PMID: 32528969 DOI: 10.3389/fmed.2020.00212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]